UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

With an estimated 2.1 million children in Nigeria and almost one million in Ethiopia1 classed as 'zero dose', having never ...

Mr Rajarshi (Rishi) Mukherjee, a Ronald Finn Senior Research Fellow has become the first recipient of the prestigious Medical ...

A programme looking to advance the understanding of how cancer develops has been backed with £50 million. Global biopharma company GSK has invested up to £50 million in a collaboration with Oxford ...

A short statement from CMS said the agency will consider ways to make Medicare price negotiations, begun under Biden, more ...

Cancer has long been one of the most feared diseases in the world. Now, a groundbreaking development in vaccine technology ...

Research from the Tufts Center for the Study of Drug Development’s PACT Consortium shows DCTs encourage higher participation ...

Vulnerable and elderly Australians are missing out on protection against respiratory syncytial virus (RSV) because many can’t afford to pay $350 for a one-off vaccine.

Shares of GSK PLC GSK inched up 0.94% to £14.01 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.28% to 8,557.81. GSK ...